Please Join 2024 RBL- NBL Network Seminar
on Tuesday November 12 at 11 am CDT. 

Dr. Ian Crozier and Dr. Jay Hooper presents a panel discussion

The threat of Monkeypox; what is it and how can we treat it?"

 Title: “The PALM0007 RCT of tecovirimat for mpox in in DR Congo: update and open questions”

Talk description: The design, operationalization, and preliminary results of the PALM007 RCT of tecovirimat will be discussed, including open questions and next steps to improve clinical outcomes in mpox caused by clade I MPXV infections in DRC.

Dr. Ian Crozier is an infectious diseases clinician-scientist at the Frederick National Lab providing chief medical officer support to NIAID’s Integrated Research Facility at Fort Detrick (IRF-Frederick). His position enables bidirectional agility between the Biosafety Level 4 animal models of high consequence and emerging viral pathogens and the human outbreak disease bedside. At the IRF, current work focuses on animal model development for filovirid diseases, Lassa Fever, and SARS-CoV-2/COVID-19. On the clinical front, primarily in clinical and research efforts in Western and Central Africa, current focus is on improving acute (and post-acute) outcomes in filovirid diseases and on optimizing clinical management of mpox as part of the PALM007 clinical trial of tecovirimat in the Democratic Republic of the Congo.

Title: “Molecular Biologics Targeting Monkeypox.”

Talk description: The evolution of nucleic acid vaccine(s) targeting mpox and will also touch on alternative biologic medical countermeasures including polyclonal and monoclonal antibodies.
 

Dr. Jay Hooper is the Chief of the Molecular Virology Branch at the United States Army Medical Research Institute of Infectious Diseases. He has more than 30 years of research experience working with lethal viruses, mostly in Biosafety Level 3 and BSL-4 high-containment. His research is aimed at the discovery and development of medical countermeasures targeting high consequence viral diseases of military importance, including hemorrhagic fever, viral encephalitis, and diseases caused by poxviruses. He has also been involved in the past decade’s public health emergencies including Ebola, Zika, COVID, and mpox. Dr. Hooper is an expert in DNA vaccine technology and the use of this technology to develop both active vaccines and passive (antibody-based) medical countermeasures. Dr. Hooper received a B.A. in Biology from Colby College in 1986 and a Ph.D. in Virology from Harvard University in 1995. His research has resulted in more than 100 peer-reviewed publications and 15 patents

If you have a question, please feel free to email Tempie Murphy at temlsyde@uthsc.edu.

JOIN

MORE INFORMATION